Alongside the highly anticipated scientific programme, EASL Studio will be broadcasting live from EASL Congress 2026 in Barcelona, delivering dynamic coverage straight from the heart of the event.
Across 10 special live episodes, viewers can stay up to date with the latest developments, expert insights, and key highlights in hepatology, bringing the energy and innovation of the congress directly to a global audience!
Programme
| 09:45 – 10:15 CEST Hola Barcelona: What not to miss during EASL Congress
Start your EASL Congress journey with a curated guide to the programme highlights. From must-see sessions and innovative formats to Young Investigator opportunities and local insights, discover how to make the most of both the science and the Barcelona experience! Debbie Shawcross (Moderator) Ana Lleo (Moderator), Thomas Marjot (YI representative), Sarwa Darwish Murad (Chair EASL Scientific Committee), Alejandro Forner (Secretary AEEH – Spanish Association for the Study of the Liver)
|
| 13:15 – 13:45 CEST Tackling MASH cirrhosis
This episode examines the risk of major adverse liver outcomes in patients with MASH cirrhosis, the complexity of therapeutic strategies, and patient heterogeneity. Experts will also discuss emerging data from ongoing trials. Mattias Mandorfer (Moderator), Khurram Jamil (Galectin Therapeutics representative), Sven Francque (Faculty), Maru Rinella (Faculty) This EASL Studio is supported by Galectin Therapeutics.
|
| 16:15 – 16:45 CEST Overcoming the barriers in PBC care: Moving theory into practice
How can we optimise PBC management in clinical practice practice? This episode explores the role of risk stratification and treatment strategies, highlights global differences in access to care, and looks ahead to emerging research and future therapeutic approaches. Emma Culver (Moderator), Phil Troke (IPSEN representative) This EASL Studio is supported by IPSEN.
|
| 10:00 – 10:30 CEST From chronicity to cure: The final frontier in HBV and HDV
What will it take to move beyond viral surpression toward cure in HBV and HDV? This episode brings together academic and industry perspectives to examine scientific barriers, emerging therapeutic strategies, and the critical steps needed to translate innovation into real-world impact. Francesco Paolo Russo (Moderator), Lawrence Blatt (Aligos Therapeutics representative), Dickens Theodore (GSK representative), Harry LA Janssen (Faculty) This EASL Studio is supported by Aligos Therapeutics and GSK.
|
| 12:45 – 13:15 CEST YI case-based discussions: Ascites, alcoholic hepatitis, and ACLF
Through three short clinical cases, this episode exlores diagnositic approaches, treatment choices, and highlights practical do’s and don’ts. Mads Israelsen (Moderator), Juan Abraldes (Faculty), Annalisa Berzigotti (Faculty), Alberto Zanetto (Faculty)
|
| 14:00 – 14:45 CEST MASH Trials 2.0: Challenges and innovation ahead
With new therapies entering clinical practice, the MASH trial landscape is shifting. This episode examines how recent approvals are reshaping recruitment, trial design, and endpoints, while exploring emerging strategies that could define the next generation of studies. Cyrielle Caussy (Moderator), Ramy Younes (Boehringer Ingelheim representative), Roberto Calle (GSK representative), Dave Soergel (Madrigal representative), Michelle Long (Novo Nordisk representative) This EASL Studio is supported by Boehringer Ingelheim, GSK, Madrigal, and Novo Nordisk.
|
| 10:00 – 10:30 CEST From HBV discovery to cure: 50 years after Blumberg’s Nobel Prize
Fifty years after Blumberg’s Nobel Prize-winning discovery of the hepatitis B surface antigen, this episode revisits the milestones that transformed HBV care. From vaccination and antivirals to evolving concepts of cure. The discussion also explores the unanswered questions in HBV biology, the future of curative therapies, and whether global elimination remains within reach. Sabela Lens (Moderator), Heiner Wedemeyer (Faculty), Thomas Tu (Patient representative), Nikolai Naoumov (Faculty)
|
| 12:45 – 13:15 CEST From evidence to action: Will the EASL-Lancet Commission 2.0 move the needle on liver disease
This episode explores the EASL–Lancet Commission 2.0 and its key priorities to advance liver health, including prevention, earlier detection, and coordinated care. It examines how these recommendations could be implemented to drive meaningful change Debbie Shawcross (Moderator), Patrizia Burra (Co-Chair EASL-Lancet Commissions), Sabine Kleinert (The Lancet), Frank Murray (Chair EHAA), Catherine Paradis (WHO Europe)
|
| 16:15 – 16:45 CEST Landmark studies at EASL Congress 2026
Which studies are shaping the future of hepatology? This episode brings together key data from EASL Congress 2026, highlighting findings with the potential to impact clinical practice and research. Sarwa Darwish Murad (Moderator), Michael Trauner (Faculty), Markus Cornberg (Faculty), Jasmohan Bajaj (Faculty)
|
| 11:45 – 12:15 CEST Adios Barcelona, hello London
As EASL Congress 2026 draws to a close, this episode looks back at key moments and milestones from the week. Join us as we celebrated achievements and look ahead to what’s next on the road to London. Debbie Shawcross, Ana Lleo (Moderators), Bogdan Procopet (EASL Scientific Committee), Francesco Paolo Russo (EASL External Affairs Councillor), Rui Castro (EASL Scientific Committee)
|